.
MergerLinks Header Logo

New Deal

New Deal

Cover Image Otello Stampacchia
Otello StampacchiaOMEGA FUNDS

Otello Stampacchia

Managing Director at OMEGA FUNDS

Investor

Deal Bio

Total Deals12
Valued Deals12
Total Value£1,852M
Avg. Deal Size£154M

Expertise (12)

Key Relationships

United States
Biotechnology
PrivatePrivate EquityAcquisitionMinorityVenture Capital
Nuvation Bio

target

Nuvation Bio

Baupost Group

bidder

Baupost Group

£214m

13 dealmakers

Switzerland
Auto Technology
PrivateAcquisitionMajorityCross BorderPrivate Equity
Andrew Alliance

target

Andrew Alliance

Waters Corporation

bidder

Waters Corporation

£61m

24 dealmakers

United States
Pharmaceuticals
AcquisitionPrivate EquityPrivateMinority
Atea Pharmaceuticals

target

Atea Pharmaceuticals

Ally Bridge Group

bidder

Ally Bridge Group

£175m

27 dealmakers

United States
Pharmaceuticals
MinorityAcquisitionVenture CapitalPrivatePrivate Equity
Kronos Bio

target

Kronos Bio

Perceptive Advisors

bidder

Perceptive Advisors

£118m

18 dealmakers

United States
Biotechnology
PrivateMajorityAcquisitionReverse TakeoverMergerDomesticPrivate EquityDe-SPAC
Nuvation Bio

target

Nuvation Bio

Panacea Acquisition Corp

bidder

Panacea Acquisition Corp

£650m

34 dealmakers

United States
Biotechnology
Private EquityAcquisitionPrivateMinorityVenture CapitalDomestic
Ikena Oncology

target

Ikena Oncology

Omega Funds

bidder

Omega Funds

£88m

15 dealmakers

United States
Medical Services
Cross BorderPrivate EquityAcquisitionPrivateMinorityVenture Capital
Icosavax

target

Icosavax

Sanofi Ventures

bidder

Sanofi Ventures

£71m

19 dealmakers

United States
Biotechnology
Venture CapitalMinorityCross BorderPrivatePrivate EquityAcquisition
Lexeo Therapeutics

target

Lexeo Therapeutics

D1 Capital Partners

bidder

D1 Capital Partners

£72m

15 dealmakers

United States
Biotechnology
MinorityPrivate EquityPrivateCross BorderVenture CapitalAcquisition
Cincor Pharma

target

Cincor Pharma

Bvf Partners

bidder

Bvf Partners

£104m

19 dealmakers

United States
Biotechnology
Venture CapitalPrivate EquityPrivateCross BorderAcquisitionMinority
Chroma Medicine

target

Chroma Medicine

Atlas Venture

bidder

Atlas Venture

£93m

12 dealmakers

United States
Biotechnology
Private EquityPrivateAcquisitionMinorityVenture CapitalCross Border
Bicara Therapeutics

target

Bicara Therapeutics

Premji Invest

bidder

Premji Invest

£89m

14 dealmakers

United States
Biotechnology
Venture CapitalDomesticPrivate EquityAcquisitionPrivateMinority
Chroma Medicine

target

Chroma Medicine

Arch Venture Partners

bidder

Arch Venture Partners

£111m

18 dealmakers

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US